title: T Cell PTLD Successfully Treated With Single-Agent Brentuximab Vedotin First-Line Therapy.
authors.affiliation: 1 Department of Nephrology and Intensive Care Medicine, Charité, Berlin, Germany. 2 Department of Nephrology, University of Heidelberg, Heidelberg, Germany. 3 DKFZ unit F100, Heidelberg, Germany. 4 Department of Nuclear Medicine, Charité, Berlin, Germany. 5 Institute of Pathology, Charité, Berlin, Germany. 6 Department of Hematology, Oncology and Tumor Immunology, Charité, Berlin, Germany.
authors.forename: Mira
authors.initials: M
authors.lastname: Choi
authors.forename: Susanne
authors.initials: S
authors.lastname: Fink
authors.forename: Vikas
authors.initials: V
authors.lastname: Prasad
authors.forename: Ioannis
authors.initials: I
authors.lastname: Anagnostopoulos
authors.forename: Petra
authors.initials: P
authors.lastname: Reinke
authors.forename: Clemens A
authors.initials: CA
authors.lastname: Schmitt
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001706:Biopsy; D000079963:Brentuximab Vedotin; D005260:Female; D006801:Humans; D018796:Immunoconjugates / Q000009:adverse effects / Q000627:therapeutic use*; D007150:Immunohistochemistry; D007166:Immunosuppressive Agents / Q000009:adverse effects; D016030:Kidney Transplantation / Q000009:adverse effects*; D016399:Lymphoma, T-Cell / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D008875:Middle Aged; D056687:Off-Label Use; D049268:Positron-Emission Tomography; D012074:Remission Induction; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D018796:Immunoconjugates; D007166:Immunosuppressive Agents; D000079963:Brentuximab Vedotin